Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Ma
Johnson & Johnson announced a voluntary agreement with the U.S. government to improve access to medicines and lower costs for millions of American patients, including participation in the TrumpRx direct‑to‑patient platform and aligning U.S. pricing closer to other developed countries. The deal also provides J&J’s pharmaceutical products with an exemption from certain U.S. tariffs and supports continued investment in domestic manufacturing infrastructure. As part of its broader commitment, the company continues to advance a previously announced $55 billion investment in U.S. manufacturing, research, and innovation through 2029. 
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Ma